Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Atezolizumab + Bevacizumab Plus Locoregional Therapies in Patients With Unresectable Hepatocellular Carcinoma in Real-world Clinical Practice

NCT07204327 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT07204327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Atezolizumab + Bevacizumab Plus Locoregional Therapies in Patients With Unresectable Hepatocellular Carcinoma in Real-world Clinical Practice
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
October 28, 2020
Completion date
December 31, 2026
Enrollment
1,136 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma